(AP)—Struggling drug company AstraZeneca outlined a major restructuring of its business on Thursday, including some 2,300 job cuts worldwide as it overhauls its research operations.
Mar 21, 2013
0
0
Results of a study published online in the Journal of Antimicrobial Chemotherapy today (Thursday), demonstrate that computer models can predict how HIV patients whose drug therapy is failing will respond to a new treatment. ...
Mar 13, 2013
0
0
Drugmaker Pfizer Inc. said Tuesday that a new patent on one of its top drugs, anti-inflammatory painkiller Celebrex, extends its U.S. patent protection by 18 months, potentially bringing the company a few billion dollars ...
Mar 5, 2013
0
0
German pharmaceuticals giant Bayer, maker of Aspirin, vowed Monday to fight a ruling by the patent authorities in India allowing a local company to produce and sell a generic copy of its anti-cancer drug Nexavar.
Mar 4, 2013
0
0
(AP)—Eli Lilly and Co. said Friday its 2013 earnings will grow more than Wall Street expects, even though the drugmaker will lose U.S. patent protection for two more key products this year.
Jan 4, 2013
0
0
(AP)—From Africa's crowded AIDS clinics to the malarial jungles of Southeast Asia, the lives of millions of ill people in the developing world are hanging in the balance ahead of a legal ruling that will determine whether ...
Jan 4, 2013
0
0
A new substance class for the treatment of multiple sclerosis and other neurodegenerative diseases now promises increased efficacy paired with fewer side effects.
Nov 26, 2012
0
0
(HealthDay)—Fascia lata, which is a thin, pliable, and vascularized tissue, can be effectively used as a substitute for nasal lining in complex total and subtotal nasal reconstruction procedures, according to a case series ...
Nov 1, 2012
0
0
For centuries, Indian housewives have used homemade remedies based on cow's milk to cure constipation—but in 2009 Swiss giant Nestle applied for a patent to protect a similar product of its own.
Oct 14, 2012
0
0
Swiss pharmaceutical giant Novartis said Sunday the expiry of a US patent for its leading hypertension drug Diovan caused a drop in turnover that could last into the first half of 2013.
Oct 7, 2012
0
0
